CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis

Thomas, E K, Cancelas, J A, Zheng, Y, Williams, D A·2008·Leukemia
DOI 10.1038/leu.2008.71
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2008.71

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 61

  1. Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830. · DOI · Paper page
  2. Michor F, Iwasa Y, Nowak MA . The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci USA 2006; 103: 14931–14934. · DOI
  3. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172. · DOI
  4. Goldman JM . Treatment of chronic myeloid leukaemia: some topical questions. Baillieres Clin Haematol 1997; 10: 405–421. · DOI · Paper page
  5. Fausel C . Targeted chronic myeloid leukemia therapy: seeking a cure. J Manag Care Pharm 2007; 13 (8 Suppl A): 8–12. · DOI
  6. Savona M, Talpaz M . Chronic myeloid leukemia: changing the treatment paradigms. Oncology (Williston Park) 2006; 20: 707–711; discussion 712–4, 719, 724.
  7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566. · DOI · Paper page
  8. Druker BJ, O’Brien SG, Cortes J, Radich J . Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2002; 1: 111–135. · DOI · Paper page
  9. Deininger MW, Goldman JM, Lydon N, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–3698. · DOI · Paper page
  10. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL . BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100: 3041–3044. · DOI · Paper page
  11. Lowenberg B . Minimal residual disease in chronic myeloid leukemia. N Engl J Med 2003; 349: 1399–1401. · DOI · Paper page
  12. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562–2569. · DOI
  13. Casalou C, Fragoso R, Nunes JF, Dias S . VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. Leukemia 2007; 21: 1590–1594. · DOI
  14. Sini P, Cannas A, Koleske AJ, Di Fiore PP, Scita G . Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation. Nat Cell Biol 2004; 6: 268–274. · DOI · Paper page
  15. Renshaw MW, Lea-Chou E, Wang JY . Rac is required for v-Abl tyrosine kinase to activate mitogenesis. Curr Biol 1996; 6: 76–83. · DOI · Paper page
  16. Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M et al. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP- binding protein Rac. Proc Natl Acad Sci USA 1998; 95: 11858–11862. · DOI · Paper page
  17. Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N . Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene 2003; 22: 6445–6454. · DOI · Paper page
  18. Burridge K, Wennerberg K . Rho and Rac take center stage. Cell 2004; 116: 167–179. · DOI · Paper page
  19. Schwartz M . Rho signalling at a glance. J Cell Sci 2004; 117 (Part 23): 5457–5458. · DOI · Paper page
  20. Blanchard JM . Small GTPases, adhesion, cell cycle control and proliferation. Pathol Biol (Paris) 2000; 48: 318–327.
  21. Gu Y, Filippi MD, Cancelas JA, Siefring JE, Williams EP, Jasti AC et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003; 302: 445–449. · DOI · Paper page
  22. Turner M, Billadeau DD . VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol 2002; 2: 476–486. · DOI
  23. Haataja L, Groffen J, Heisterkamp N . Characterization of RAC3, a novel member of the Rho family. J Biol Chem 1997; 272: 20384–20388. · DOI · Paper page
  24. Cho YJ, Zhang B, Kaartinen V, Haataja L, de Curtis I, Groffen J et al. Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia. Mol Cell Biol 2005; 25: 5777–5785. · DOI · Paper page
  25. Mira JP, Benard V, Groffen J, Sanders LC, Knaus UG . Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway. Proc Natl Acad Sci USA 2000; 97: 185–189. · DOI
  26. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005; 24: 7821–7829. · DOI · Paper page
  27. Zhang X, Ren R . Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829–3840. · DOI
  28. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175–185. · DOI
  29. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764–773. · DOI
  30. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479–492. · DOI
  31. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ . Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925–22928. · DOI
  32. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M et al. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 1995; 11: 899–907.
  33. Wertheim JA, Perera SA, Hammer DA, Ren R, Boettiger D, Pear WS . Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood 2003; 102: 2220–2228. · DOI
  34. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766–5774. · DOI
  35. Nishihara H, Maeda M, Oda A, Tsuda M, Sawa H, Nagashima K et al. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 2002; 100: 3968–3974. · DOI · Paper page
  36. Sattler M, Verma S, Pride YB, Salgia R, Rohrschneider LR, Griffin JD . SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem 2001; 276: 2451–2458. · DOI · Paper page
  37. Miranda MB, Johnson DE . Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007; 21: 1363–1377. · DOI
  38. Carlesso N, Frank DA, Griffin JD . Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811–820. · DOI
  39. Ilaria Jr RL, Van Etten RA . P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271: 31704–31710. · DOI
  40. Lin TS, Mahajan S, Frank DA . STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19: 2496–2504. · DOI
  41. Hoover RR, Gerlach MJ, Koh EY, Daley GQ . Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001; 20: 5826–5835. · DOI
  42. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W . Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002; 30: 262–271. · DOI
  43. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229–1242. · DOI
  44. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95: 2118–2125. · DOI · Paper page
  45. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109: 2147–2155. · DOI
  46. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 2000; 96: 2277–2283. · DOI
  47. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107: 4898–4906. · DOI
  48. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y . Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 2004; 101: 7618–7623. · DOI · Paper page
  49. Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111. · DOI · Paper page
  50. Williams DA, Cancelas JA . Leukaemia: niche retreats for stem cells. Nature 2006; 444: 827–828. · DOI
  51. Krause DS, Lazarides K, von Andrian UH, Van Etten RA . Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175–1180. · DOI · Paper page
  52. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167–1174. · DOI
  53. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371–2378. · DOI
  54. Lin CS, Lim SK, D’Agati V, Costantini F . Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996; 10: 154–164. · DOI
  55. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW . The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 2000; 79: 424–431. · DOI
  56. Guo JQ, Wang JY, Arlinghaus RB . Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991; 51: 3048–3051.
  57. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV . Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005; 105: 4893–4894. · DOI
  58. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707. · DOI
  59. Deininger MW . Optimizing therapy of chronic myeloid leukemia. Exp Hematol 2007; 35 (4 Suppl 1): 144–154. · DOI
  60. Melo JV, Barnes DJ . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441–453. · DOI
  61. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098. · DOI

Cited by

See all 60

Metadata

Authors
Thomas, E. K., Cancelas, J. A., Zheng, Y., & Williams, D. A.
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2008-03-20
Volume
22
Issue
5
Pages
898-904
ISSN
  • 0887-6924
  • 1476-5551
DOI
10.1038/leu.2008.71
Cited by
60
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review